在使用华法林的患者中,减少抗血小板使用而没有胃保护的干预措施:AEGIS集群随机试验
Jacob E Kurlander1,2,3, Danielle Helminski1, Xueting Tao4
1Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States.
Thrombosis and haemostasis
|May 2, 2025
概括
一项多组分干预措施减少了华法林患者不必要的抗血小板使用. 这种临床医生通知与护士便利化 (CNNF) 策略增加了药物改变,降低了胃肠道出血风险.
科学领域:
- 临床药房 临床药房
- 药理学 药理学是指药理学的学科.
- 患者安全 患者安全
背景情况:
- 许多服用华法林等抗凝血剂的患者也服用抗血小板药物.
- 这种组合,没有胃保护 (例如,质子抑制剂 - PPI),显著提高胃肠道出血的风险.
- 当前的处方做法往往无法充分解决这种高风险的药物重叠问题.
研究的目的:
- 评估临床医生通知与护士促进 (CNNF) 干预的有效性.
- 为了减少高风险的同时处方抗血小板药物在华法林患者不接受PPI.
- 通过减轻胃肠道出血风险来提高患者的安全.
主要方法:
- 实施了多组件干预,包括电子临床医生通知和护士便利.
- 护士们发现了在没有PPI的情况下服用华法林和抗血小板药物的患者,并建议对药物进行审查.
- 测量结果包括自我报告的抗血小板药物停用或PPI启动,以及记录的临床医生建议.
主要成果:
- 该CNNF干预显著增加了患者停止抗血小板治疗或启动PPI的几率 (aOR 5.76).
- 一个修改后的补充分析显示了更强的效果 (aOR 43.6).
- 在干预组中,临床医生对药物改变的建议大大高于干预组 (68.2%对0.9%).
结论:
- 该CNNF干预措施有效地促使对华法林和抗血小板药物的患者进行必要的药物调整.
- 这一策略成功导致了抗血小板药物停用或PPI启动,提高了患者的安全性.
- 有针对性的干预措施可以改善处方实践,减少与药物相关的不良事件.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
388
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
388
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
991
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
991
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
536
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
536
01:22Formation of the Platelet Plug
2.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
2.7K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
97
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
97
01:26Peptic Ulcer Disease IV: Management
45
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
45